NewGenIvf Group (NASDAQ:NIVF) Major Shareholder Sells $68,253.60 in Stock

NewGenIvf Group Limited (NASDAQ:NIVFGet Free Report) major shareholder Financial Lp Hrt sold 85,317 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $0.80, for a total transaction of $68,253.60. Following the completion of the sale, the insider owned 54,561 shares of the company’s stock, valued at approximately $43,648.80. This represents a 60.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

  • On Tuesday, May 26th, Financial Lp Hrt acquired 27,993 shares of NewGenIvf Group stock. The shares were purchased at an average price of $0.92 per share, with a total value of $25,753.56.
  • On Friday, May 22nd, Financial Lp Hrt acquired 137,541 shares of NewGenIvf Group stock. The shares were purchased at an average price of $0.99 per share, with a total value of $136,165.59.

NewGenIvf Group Price Performance

Shares of NASDAQ NIVF traded up $0.12 during trading hours on Thursday, hitting $0.97. 3,389,162 shares of the stock were exchanged, compared to its average volume of 1,436,935. The company has a current ratio of 3.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.16. The firm has a fifty day moving average price of $1.68 and a 200-day moving average price of $6.93. NewGenIvf Group Limited has a 12 month low of $0.72 and a 12 month high of $1,839.00.

NewGenIvf Group (NASDAQ:NIVFGet Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($287.24) EPS for the quarter. The company had revenue of $1.42 million for the quarter. As a group, sell-side analysts predict that NewGenIvf Group Limited will post 4.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a research note on Monday, April 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on NewGenIvf Group

NewGenIvf Group Company Profile

(Get Free Report)

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.

Featured Stories

Receive News & Ratings for NewGenIvf Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewGenIvf Group and related companies with MarketBeat.com's FREE daily email newsletter.